Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bap-Notch engineered mesenchymal stromal cells
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intracerebral
01
Overview
Bap-Notch engineered mesenchymal stromal cells (MSCs) are an experimental cell-based therapy designed for the treatment of Alzheimer's disease. Developed by researchers at Vanderbilt University, these cells are modified using the synthetic Notch (synNotch) platform to express a chimeric receptor. The extracellular domain of this receptor utilizes a single-chain variable fragment (scFv) derived from the anti-amyloid-beta (Aβ) monoclonal antibody bapineuzumab. Upon encountering and binding to Aβ aggregates in the brain, the synNotch receptor undergoes intramembrane proteolysis, releasing an intracellular synthetic transcription factor. This factor then translocates to the nucleus to drive the expression of programmed therapeutic transgenes, such as anti-inflammatory agents (e.g., soluble TNF receptor 1 and IL-1 receptor antagonist). This localized, inducible approach aims to combine the innate immunomodulatory properties of MSCs with targeted, disease-responsive delivery of potent therapeutics to mitigate neuroinflammation and protein aggregation.
- Other names
- Bap-Notch MSCsbapineuzumab-synNotch engineered mesenchymal stromal cells
02
Targets
Aβ (Amyloid-beta peptides and aggregates)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Bap-Notch engineered mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bap-Notch engineered mesenchymal stromal cells.